Program
AK138D1
A development code.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms, led by Akeso.
Furthest: phase 2, since Apr 24, 20264 company-led studies, 4 open or runningNext primary completion: Feb 26, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Akeso | 44 open or running | phase 2since Apr 24, 2026 | Dec 9, 2024 | Feb 26, 2028phase 1 · NCT06730386 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 9, 2024First study: phase 1 study in Solid CancerFirst studyNCT06730386 · 100 planned · Australia
- Sep 25, 2025Phase 1 study in Solid CancerNCT07281326 · 200 planned · China
- Apr 24, 2026Phase 2 study in Breast NeoplasmsPhase 2 reachedNCT07560124 · 286 planned · China
- May 28, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07623356 · 265 planned · China
Ahead
- Feb 26, 2028Primary completion: phase 1 study in Solid CancerNCT06730386
- Jun 6, 2028Primary completion: phase 2 study in Breast NeoplasmsNCT07560124
- Jun 18, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07623356
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07623356Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Jun 18, 2028 | 265 |
| NCT07560124Breast Neoplasms · China | 2 | Not yet recruiting | Jun 6, 2028 | 286 |
| NCT07281326Solid Cancer · China | 1 | Recruiting | Oct 22, 2026 | 200 |
| NCT06730386Solid Cancer · Australia | 1 | Recruiting | Feb 26, 2028 | 100 |
How it is read
Names in the registry
- “AK138D1”, 4 entries
Codes read as this program: AK138D1.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.